Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

Also called NCT03984760

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 240 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03984760
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03984760. Randomized; no masking; primary purpose treatment. Start 2019-06-19 (actual); primary completion 2021-02-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
Condition
Hyperphosphatemia
Condition
End Stage Renal Disease
Condition
ESRD
Intervention (Drug)
Ferric Citrate
Intervention (Drug)
Sevelamer Carbonate
Lead sponsor
Panion & BF Biotech Inc. (class: industry)
Collaborator
Shandong Weigao Panion Pharmaceutical Co. Ltd. (class: not stated)

Record details

Record id
cardio:ct-nct03984760
Content hash
b3cdcb66c3fcd84a7ec29ca02e4c80a28f8435001bb6c94fe95212136a595978